Our portfolio
KDventure’s portfolio consists of life science companies with the potential to address significant medical needs and create long-term value. Here you get an overview of the companies’ projects, development phases and upcoming key milestones.
Our portfolio and its development
The portfolio companies develop highly differentiated and commercially attractive products with the potential to deliver both compelling clinical and health-economic benefits, as well as attractive returns. Here you can see an overview of the pharmaceutical and medtech portfolio.
10
Portfolio companies
4
Late-stage clinical projects
5
Target year 2026
Så läser du pilen
Mörkblå = Avklarat
Ljusblå = Påbörjat
Grå = Ej påbörjat
Dilafor
Pharmaceuticals
Induction of labour
Target year 2027
BOOST Pharma
Pharmaceuticals
Osteogenesis imperfecta
Target year 2029
Umecrine Cognition
Pharmaceuticals
Primary biliary cholangitis
Target year 2026
Parkinson's disease
Target year –
Modus Therapeutics
Pharmaceuticals
Sepsis/septic chock
Target year 2027
Anemia chronic inflammation/kidney disease
Target year 2026
Severe malaria
Target year –
AnaCardio
Pharmaceuticals
Heart failure
Target year 2028
PharmNovo
Pharmaceuticals
Neuropathic pain
Target year 2027
SVF Vaccines
Pharmaceuticals
Hep. B/D
Target year 2027
Covid-19
Target year –
CCHF
Target year 2026
Aprea Therapeutics
Pharmaceuticals
DDR i oncology
Target year 2026
Biosergen
Pharmaceuticals
Promimic
Medtech
Medical implant coatings
Target year –
No project matches the search criteria.